Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.

Anderson, Sarah M; Beck, Bradley; Sterud, Susan; Lockhorst, Robin; Ngorsuraches, Surachat

Anderson, Sarah M; Beck, Bradley; Sterud, Susan; Lockhorst, Robin; Ngorsuraches, Surachat.

Affiliation

Anderson SM; 1 Department of Pharmacy, Avera McKennan Hospital and University Health Center, Sioux Falls, USA.
Beck B; 2 Department of Pharmacy, Avera Cancer Institute, Sioux Falls, USA.
Sterud S; 2 Department of Pharmacy, Avera Cancer Institute, Sioux Falls, USA.
Lockhorst R; 2 Department of Pharmacy, Avera Cancer Institute, Sioux Falls, USA.
Ngorsuraches S; 3 Department of Pharmacy Practice, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, USA.

J Oncol Pharm Pract ; 25(4): 806-812, 2019 Jun.

Article in En | MEDLINE | ID: mdl-29486638

Subject(s)

Anticoagulants/therapeutic use; Lenalidomide/therapeutic use; Multiple Myeloma/drug therapy; Thalidomide/analogs & derivatives; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Pulmonary Embolism/epidemiology; Pulmonary Embolism/prevention & control; Retrospective Studies; Thalidomide/therapeutic use; Venous Thromboembolism/epidemiology; Venous Thromboembolism/prevention & control

Key words

Lenalidomide; anticoagulation prophylaxis; multiple myeloma; pomalidomide; thromboembolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Thalidomide / Lenalidomide / Multiple Myeloma / Anticoagulants Type of study: Guideline / Observational_studies / Risk_factors_studies Language: En Journal: J Oncol Pharm Pract Year: 2019 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google